Compugen (CGEN) Receives Media Impact Score of 0.13
Headlines about Compugen (NASDAQ:CGEN) have trended somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Compugen earned a news impact score of 0.13 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.7245066774099 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news stories that may have impacted Accern’s analysis:
- Compugen Reports Third Quarter 2017 Results – Markets Insider (markets.businessinsider.com)
- Head-To-Head Survey: Compugen (CGEN) versus Quintiles Transitional Holdings (Q) (americanbankingnews.com)
- Compugen’s (CGEN) CEO Anat Cohen-Dayag on Q3 2017 Results – Earnings Call Transcript (seekingalpha.com)
- Compugen reports 3Q loss (finance.yahoo.com)
Separately, Zacks Investment Research upgraded Compugen from a “sell” rating to a “hold” rating in a report on Tuesday, October 3rd.
Shares of Compugen (NASDAQ:CGEN) opened at $2.45 on Tuesday. Compugen has a twelve month low of $2.35 and a twelve month high of $6.75.
COPYRIGHT VIOLATION WARNING: This article was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/11/14/compugen-cgen-receives-media-impact-score-of-0-13.html.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.
Receive News & Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.